Pancholi S, Leal MF, Ribas R, Simigdala N, et al. Correction to: Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer. Breast Cancer Res 2020;22:14.
PMID: 32005287